Application of Bayesian Modeling with Infliximab to Determine Optimal Patient Specific Regimen
Timothy E. Ritter, MD – Texas Digestive Disease Consultants, Southlake, TX, U.S.
Harry E. Sarles, MD – DHAT Research Institute, Garland, TX, U.S.
Robert C. McLeay, PhD – DoseMeRx, Brisbane, Australia
Lucinda J. Van Anglen, PharmD – Healix LLC, Sugar Land, TX, U.S.
Claudia P. Schroeder, PharmD, PhD – Healix LLC, Sugar Land, TX, U.S.